Thrombosis Research Institute to announce new real-world GARFIELD-AF registry insights in atrial fibrillation at ESC Congress 2016


AF_GARFIELDNew analyses from the Global Anticoagulant Registry in the Field-Atrial Fibrillation (GARFIELD-AF) will be presented at the European Society of Cardiology (ESC) Congress (27‒31 August, Rome, Italy) with a focus on the importance of risk stratification and tailored management strategies to inform the evolution of everyday clinical practice. Better risk stratification schemes and appropriately prescribed and monitored antithrombotic therapy can help physicians to reduce the incidence of stroke in patients with atrial fibrillation (AF).

GARFIELD-AF is the largest ongoing prospective AF registry, and enrolment is now complete, with over 57,000 patients recruited across five cohorts. This year, a new risk stratification tool based on the global data from GARFIELD-AF will be unveiled at the ESC Registry Session on AF to be held on Monday 29 August at 8:30.

Risk assessment now focuses on improved identification of truly low-risk patients with AF who do not need any antithrombotic therapy using risk stratification tools. This session, to be presented by Keith AA Fox (University of Edinburgh, Edinburgh, United Kingdom) will compare the performance of CHA2DS2-VASc with a novel computer-generated (machine learning) approach to risk modelling for low-risk patients with AF using contemporary data from GARFIELD-AF.

Further insights from GARFIELD-AF will be presented in a Satellite Symposium and two moderated poster presentations:

The Satellite Symposium titled: “Risk profiles and the quality of stroke prevention for patients with atrial fibrillation: Results from the GARFIELD-AF registry” has been sponsored by the Thrombosis Research Institute. It will be held on Saturday 27 August from 15:30 to 17:00.

An expert faculty will explore questions using data from newly diagnosed patients with AF in GARFIELD-AF, on topics including the risk of early mortality, risk scoring schemes for patients, management of low-risk patients and the characteristics of patients receiving different antithrombotic therapies.

Keith AA Fox will also present an analysis of geographical variability in all-cause mortality, stroke/systemic embolism and major bleeding observed in patients with newly diagnosed non-valvular AF from GARFIELD-AF in a moderated poster session on Monday 29 August from 15:35 to 16:25.

Shinya Goto (Tokai University, Isehara, Japan) will present an analysis of the association between international normalised ratios, used to measure of the intensity of anticoagulation, and the rates of stroke/systemic embolism, major bleeding and all-cause mortality in patients from Eastern and Southeastern Asia receiving vitamin K antagonists (based on data from GARFIELD-AF) in a moderated poster session on Tuesday 30 August from 10:05 to 10:55.